StockWatch
·
Biotechnology: Biological Products (No Diagnostic Substances)
Board MeetingNov 20, 2026, 04:01 PM

Kymera Therapeutics to Announce Atopic Dermatitis Trial Results Nov. 23

AI Summary

Kymera Therapeutics, Inc. announced that it will report results from its BROADEN2 Phase 2b clinical trial for KT-621, an oral STAT6 degrader, in patients with moderate to severe atopic dermatitis on Monday, November 23, 2026. A press release detailing the results will be issued at 7:00 a.m. ET, followed by a video conference call and webcast at 8:00 a.m. ET. KT-621 is being developed as a potential treatment for various Type 2 inflammatory diseases.

Key Highlights

  • Kymera Therapeutics to announce results from BROADEN2 Phase 2b clinical trial for KT-621 in atopic dermatitis on November 23, 2026.
  • Press release with results to be issued at 7:00 a.m. ET.
  • Video conference call and webcast to follow at 8:00 a.m. ET.
  • KT-621 is an investigational oral degrader of STAT6 for Type 2 inflammation.
  • KT-621 is also in clinical development for asthma.
  • Potential to treat atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, and bullous pemphigoid.